Alzamend Neuro, Inc.ALZN
Price (close)
$1.83
Market cap
$8.8M
P/E
—
Revenue (TTM)
—
Net income
-$9.1M
Dividend yield
—
1-year total return
-22.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Alzamend Neuro, Inc. does.
our two product candidates, we aim to bring treatments or potential cures to market as quickly as possible. Far too many individuals,
including patients and caregivers, suffer from the burden created by these devastating, and often fatal, diseases or disorders. Our primary
target, Alzheimer’s, is among the most-feared diseases (second only to cancer) among Americans, according to a 2024 Center for Disease
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net income | -$5.0M | -$12.4M | -$14.9M | -$9.9M | -$4.5M | -$8.8M |
More on ALZN.
- Alzamend Neuro, Inc. summary
- Alzamend Neuro, Inc. financial statements
- Alzamend Neuro, Inc. key metrics
- Alzamend Neuro, Inc. health scores and style box
- Alzamend Neuro, Inc. earnings
- Alzamend Neuro, Inc. dividends
- Alzamend Neuro, Inc. valuation
- Alzamend Neuro, Inc. ownership and insiders
- Alzamend Neuro, Inc. peers
Figures from Alzamend Neuro, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.